Which of the following is NOT a commonly monitored adverse effect with Filgrastim therapy?

• A. Hypoglycemia
• B. Leukocytosis
• C. Bone pain
• D. Splenomegaly

Answer: (A)

Filgrastim stimulates the bone marrow to produce neutrophils, so leukocytosis is a typical and routinely monitored effect. The increased marrow activity can also cause bone pain, another commonly tracked adverse effect. Splenomegaly can occur with G-CSF therapy and is monitored to catch potential complications early. Hypoglycemia, however, is not a typical adverse effect of filgrastim therapy and is not routinely monitored in this context, making it the option that does not fit with the others.